Sarepta

Sarepta Marks A 'Very Important Day' For The DMD Community

Sarepta, T-Mobile Make Moves After-Hours Following Earnings Results

Down 16% Over May, Has Sarepta Become A Cheap Takeout Target?

Sarepta, T-Mobile Make Moves After-Hours Following Earnings Results

Down 16% Over May, Has Sarepta Become A Cheap Takeout Target?

The Street Is Misreading Sarepta's Guidance

FDA 101: What Does 'Orphan Drug Designation' Mean?

The Street Is Misreading Sarepta's Guidance

FDA 101: What Does 'Orphan Drug Designation' Mean?

Sarepta Soars Following Encouraging Exondys 51 News

Credit Suisse Says Sarepta Shares Volatile, Still A Favorite Idea

Sarepta Recent News

2 Opposing Views On The Future Of Sarepta

A Timeline Of PTC Therapeutics' Translarna Journey

3 Reasons 2017 Launch Expectations For Sarepta's EXONDYS 51 Are 'Too High'

Sarepta Shares Fall After Anthem Blue Cross Finds Issue With Eteplirsen

DMD Deal With Summit Is 'Low Risk, High Reward' For Sarepta

Sarepta Prices Newly-Approved DMD Drug, Cowen Upgrades Stock To Outperform

Sarepta Analysts Turn Bullish After Duchenne Muscular Dystrophy Drug Eteplirsen Gets Approval

Sarepta's Eteplirsen Receives Accelerated FDA Approval, Shares Soar 80%

Why Did Sarepta Therapeutics Plunge 20%?

Sarepta Therapeutics Surges 20% On No News

Sarepta Spikes 20%, Feuerstein Says Company Can Win FDA Drug Approval

The Street's Feuerstein Breaks Down Sarepta's 40% Plunge

Sarepta Therapeutics Gives Up Gains Following Notable Tweet

Investors Rewarded With Treats, Not Tricks, As Dow And S&P Close At Record Highs

Barron's Recap: Sunny Skies For Home Depot

Market Wrap For January 16: Markets End Two Day Winning Streak